Taking stock of the drug industry, from the lab to the medicine chestFebruary 10, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer PATRICK T. FALLON/AFP via Getty Images STAT+ | Generics companies fought to stop the new drug pricing law. But they may end up benefiting Generic drugmakers lobbied hard against letting Medicare negotiate drug prices. But they may end up benefiting from it. By John Wilkerson As ban on one abortion pill looms, providers look to the other as a fallback. But that isn't ideal This month, a federal court judge could rule on whether to overrule the FDA's approval of the abortion drug mifepristone in 2000. By Eric Boodman STAT+ | Medicare details forthcoming penalties for drug price hikes The administration explained how it's planning to enact a new law that will penalize drugmakers for hiking their prices faster than inflation. By Rachel Cohrs Hyacinth Empinado/STAT STAT+ | A CAR-T from Bristol Myers benefits myeloma patients at earlier stage of care The CAR-T cancer therapy called Abecma reduced the risk of multiple myeloma relapse by half compared to standard treatment. By Adam Feuerstein STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments